Skip to main content
. 2016 Jan 6;48(3):1110–1119. doi: 10.4143/crt.2015.289

Fig. 2.

Fig. 2.

(A) Median time of continued epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) after first progressive disease for patient groups according to patterns of progression in skeletal metastasis. (B) Postskeletal metastasis progression survival for patient groups according to patterns of progression in skeletal metastasis.